

Ronald Reagan Presidential Library
Digital Library Collections

This is a PDF of a folder from our textual collections.

WHORM Subject File Code: HE006-01
(Health: Narcotics)
Case file Number(s): 139149-140499
Box: 7

To see more digitized collections visit:
<https://www.reaganlibrary.gov/archives/digitized-textual-material>

To see all Ronald Reagan Presidential Library inventories visit:
<https://www.reaganlibrary.gov/archives/white-house-inventories>

Contact a reference archivist at: **reagan.library@nara.gov**

Citation Guidelines: <https://reaganlibrary.gov/archives/research-support/citation-guide>

National Archives Catalogue: <https://catalog.archives.gov/>

139381
J/E006-01

DB

ID: 139381 CORRESPONDENCE TRACKING WORKSHEET PAGE D01
INCOMING CORRESPONDENCE DATE 830519 RECEIVED DATE 830523
(PREFIX) (FIRST) (LAST) (SUFFIX)
THE HONORABLE J. ROY ROWLAND
TITLE:

ORGANIZATION: U. S. HOUSE OF REPRESENTATIVES

STREET:

CITY: WASHINGTON STATE: DC ZIP: 20515
COUNTRY:

SUBJECT: REQUESTS OFFICIAL WHITE HOUSE POLICY ON
H.R. 1097, RELATIVE TO RECLASSIFYING THE DRUG
METHAQUALONE

AGY/OFF ACTION CODE TRACKING DATE
LADUBE ORG 830523

KD A 830806

STAFF NAME: KENNETH DUBERSTEIN MEDIA: L OPID: LW TYPE: IBA
COMMENTS:

CODES: REPORT INDIV: 1230 USER:

PD Nayer
LA Dubbe

D 830610
A 830708

C 830708

100
July 18, 1983

139381

HE 006-01

ER

Dear Mr. Rowland:

We have reviewed your letter requesting clarification of our position on your legislation for reclassifying the drug methaqualone.

The Administration's position on H.R. 1097 is that the proposed legislation would not accomplish its intended purpose of reducing methaqualone abuse in the United States and may, in fact, pose potential disadvantages to efforts to control the diversion of methaqualone and other legitimately manufactured substances. This position is based upon currently existing circumstances. As you know, administrative mechanisms exist for the rescheduling of methaqualone from Schedule II to Schedule I, should these circumstances change and such action be deemed appropriate.

Methaqualone continues to have an accepted medical use. Therefore, the rescheduling of methaqualone within the United States into a category of no accepted medical use would not be accurate and could prejudice the future effectiveness of the existing regulatory system. The principal source of illicit methaqualone is diversion from legitimate international commerce into an illegal distribution system which would not be affected by rescheduling action.

A major element of the current U.S. strategy has been to encourage producing and distribution countries to limit the manufacture and exportation of methaqualone to that required for minimal legitimate medical needs under its existing schedule. These initiatives have been effective and should be continued. Germany, Austria, Hungary and the People's Republic of China have all agreed to reduce or cease methaqualone production and to place strict controls on its exportation. As a result of these actions, methaqualone-related injuries have decreased by 40 percent since 1980.

In addition, the Food and Drug Administration and the Drug Enforcement Administration have undertaken an official review of the methaqualone control issue. We want to bring all existing resources to bear on reducing methaqualone abuse in the United States.

I hope that the above clarification meets your needs and will prevent any further misunderstanding of the position of the Administration.

With best wishes,

Sincerely,

Kenneth M. Duberstein
Assistant to the President

The Honorable J. Roy Rowland
House of Representatives
Washington, D.C. 20515

cc: Carlton Turner - FYI

KMD:OPD:CMP:vml--

THE WHITE HOUSE

WASHINGTON

July 8, 1983

MEMORANDUM FOR KENNETH M. DUBERSTEIN

FROM: CARLTON TURNER

SUBJECT: Congressman Rowland and H.R. 1097

Attached as requested is a draft response to Congressman Rowland concerning the Administration's position on his proposed legislation to reclassify the drug methaqualone.

For your information, I advised Congressman Rowland that I would not actively oppose the bill unless I was specifically requested to respond.

Following this discussion, I was contacted by reporters from ABC and the local media in Georgia and Florida concerning this bill, all of whom had been referred to me by Congressman Rowland's office.

In addition, I learned that the Community Correspondents Group, which represents the parent movement, was in the process of preparing an article which would result in a massive letter writing campaign in support of this bill. The article had been initiated by an ACTION employee who happens to be the next-door neighbor of Congressman Rowland in Georgia. The head of the Community Correspondents Group cancelled the article after learning that the Administration does not support rescheduling by Congressional mandate. The ACTION employee was also notified of the Administration position and has been reminded to support it.

In both instances, I was specifically requested to respond and did so.

June 6, 1983

Dear Mr. Rowland:

Thank you for your letter requesting clarification of our position on your legislation for reclassifying the drug methaqualone.

I appreciate your bringing your concerns to our attention. I have taken the liberty of sharing your letter with the Office of Policy Development here, and should be hearing further following the necessary review.

With best wishes,

Sincerely,

Kenneth M. Duberstein
Assistant to the President

The Honorable J. Roy Rowland
House of Representatives
Washington, D.C. 20515

KMD:CMP:dps

cc: w/copy of inc, Ed Harper --ATTN:
CARLTON TURNER-- for DRAFT response

WH RECORDS MANAGEMENT WILL RETAIN ORIGINAL
INCOMING

J. ROY ROWLAND
6TH DISTRICT, GEORGIA

COMMITTEES:
PUBLIC WORKS AND TRANSPORTATION
VETERANS' AFFAIRS

WASHINGTON OFFICE:
513 CANNON HOUSE OFFICE BUILDING
WASHINGTON, D.C. 20515
(202) 225-6531

739381

Congress of the United States
House of Representatives
Washington, D.C. 20515

DISTRICT OFFICES:
ROOM 203, FEDERAL BUILDING
DUBLIN, GEORGIA 31021
(912) 275-0024

POST OFFICE BOX 6258
MACON, GEORGIA 31208
(912) 743-0150

ROOM 207, FEDERAL BUILDING
WAYCROSS, GEORGIA 31501
(912) 285-8420

May 19, 1983

Mr. Kenneth M. Duberstein
Assistant to the President
for Legislative Affairs
The White House
1600 Pennsylvania Avenue, N.W.
Washington, D. C. 20500

Dear Mr. Duberstein:

In light of recent conversations with Randy Davis and Doctor Carlton Turner of the White House, I find it necessary to bring to your attention the serious concerns I have regarding official White House policy on legislation I have introduced to reclassify the drug methaqualone.

Although Mr. Davis has been extremely helpful in resolving a rather confusing matter, I feel I must express my opinion that certain actions taken by Doctor Turner involving this bill appear to be somewhat contradictory in nature.

At the heart of my concern is legislation I have introduced which would move methaqualone from Schedule II to I of the Controlled Substances Act. In previous communication with Doctor Turner, I was advised that the Administration's position was that this action was administrative and under the jurisdiction of the Food and Drug Administration. However, I was further advised that there would be no efforts to actively oppose the bill.

Unfortunately, some weeks later I discovered that a national parents' organization was expressly requested by Doctor Turner to halt the release of a newsletter urging support of this legislation. Now I certainly share Doctor Turner's concern that constituents be well-informed on issues in which they contact Members of Congress; but, in my opinion Doctor Turner's action in this regard constitutes active opposition.

Therefore, I believe written clarification of the official White House position on H.R. 1097 would be in order. I am confident that this course of action will prevent any further misunderstanding of the position of the Administration.

Sincerely,


J. ROY ROWLAND

OFFICE OF POLICY DEVELOPMENT

STAFFING MEMORANDUM

DATE: 6/13/83 ACTION/CONCURRENCE/COMMENT DUE BY: June 24, 1983

SUBJECT: J. ROY ROWLAND REQUESTS OFFICIAL WHITE HOUSE POLICY ON H.R. 1097,
RELATIVE TO RECLASSIFYING THE DRUG METHAQUALONE

	ACTION	FYI		ACTION	FYI
HARPER	☐	☐	DRUG POLICY	☐	☐
PORTER	☐	☐	TURNER	☐	☐
BARR	☐	☐	D. LEONARD	☐	☐
BLED SOE	☐	☐	OFFICE OF POLICY INFORMATION		
BOGGS	☐	☐	HOPKINS	☐	☐
BRADLEY	☐	☐	PROPERTY REVIEW BOARD	☐	☐
CARLESON	☐	☐	OTHER		
DENEND	☐	☐		☐	☐
GALEBACH	☐	☐		☐	☐
GARFINKEL	☐	☐		☐	☐
GUNN	☐	☐		☐	☐
B. LEONARD	☐	☐		☐	☐
LI	☐	☐		☐	☐
McALLISTER	☐	☐		☐	☐
MONTOYA	☐	☐		☐	☐
ROPER	☐	☐		☐	☐
SMITH	☐	☐		☐	☐
SWEET	☐	☐		☐	☐
UHLMANN	☐	☐		☐	☐
✓ ADMINISTRATION	☒	☐		☐	☐

REMARKS:

THE WHITE HOUSE

WASHINGTON

July 8, 1983

MEMORANDUM FOR KENNETH M. DUBERSTEIN

FROM: CARLTON TURNER

SUBJECT: Congressman Rowland and H.R. 1097

Attached as requested is a draft response to Congressman Rowland concerning the Administration's position on his proposed legislation to reclassify the drug methaqualone.

For your information, I advised Congressman Rowland that I would not actively oppose the bill unless I was specifically requested to respond.

Following this discussion, I was contacted by reporters from ABC and the local media in Georgia and Florida concerning this bill, all of whom had been referred to me by Congressman Rowland's office.

In addition, I learned that the Community Correspondents Group, which represents the parent movement, was in the process of preparing an article which would result in a massive letter writing campaign in support of this bill. The article had been initiated by an ACTION employee who happens to be the next-door neighbor of Congressman Rowland in Georgia. The head of the Community Correspondents Group cancelled the article after learning that the Administration does not support rescheduling by Congressional mandate. The ACTION employee was also notified of the Administration position and has been reminded to support it.

In both instances, I was specifically requested to respond and did so.

THE WHITE HOUSE

WASHINGTON

July 8, 1983

Dear Congressman Rowland:

We have reviewed your letter requesting clarification of our position on your legislation for reclassifying the drug methaqualone.

The Administration's position on H.R. 1097 is that the proposed legislation would not accomplish its intended purpose of reducing methaqualone abuse in the United States and may, in fact, pose potential disadvantages to efforts to control the diversion of methaqualone and other legitimately manufactured substances. This position is based upon currently existing circumstances. As you know, administrative mechanisms exist for the rescheduling of methaqualone from Schedule II to Schedule I, should these circumstances change and such action be deemed appropriate.

Methaqualone continues to have an accepted medical use. Therefore, the rescheduling of methaqualone within the United States into a category of no accepted medical use would not be accurate and could prejudice the future effectiveness of the existing regulatory system. The principal source of illicit methaqualone is diversion from legitimate international commerce into an illegal distribution system which would not be affected by rescheduling action.

A major element of the current U.S. strategy has been to encourage producing and distribution countries to limit the manufacture and exportation of methaqualone to that required for minimal legitimate medical needs under its existing schedule. These initiatives have been effective and should be continued. Germany, Austria, Hungary and the People's Republic of China have all agreed to reduce or cease methaqualone production and to place strict controls on its exportation. As a result of these actions, methaqualone-related injuries have decreased by 40 percent since 1980.

In addition, the Food and Drug Administration and the Drug Enforcement Administration have undertaken an official review of the methaqualone control issue. We want to bring all existing resources to bear on reducing methaqualone abuse in the United States.

I hope that the above clarification meets your needs and will prevent any further misunderstanding of the position of the Administration.

Sincerely,

Kenneth M. Duberstein
Assistant to the President

The Honorable J. Roy Rowland
U.S. House of Representatives
Washington, D.C. 20515

June 28, 1983

MEMORANDUM FOR CARLTON TURNER

FROM:

DAN LEONARD



SUBJECT:

ANGIE HAMMOCK AND DR. ROWLAND

During the McNeil trip to New England it became obvious to me that Angie has more than a passing interest in supporting the passage of Congressman Rowland's bill to reschedule METHAQUALONE. In one conversation she argued for the rescheduling of METHAQUALONE by the Congress.

If it is the position of this Administration that we oppose rescheduling by Congressional mandate then Angie should be informed so that she will support our position.

MEMORANDUM

THE WHITE HOUSE

WASHINGTON

June 14, 1983

FOR: CARLTON TURNER

FROM: JUDY JOHNSTON

SUBJECT: Attached Correspondence

Attached is a letter to Ken Duberstein from Rep. Rowland regarding Methaqualone. Duberstein has forwarded the letter to us for preparation of a further response for his signature.

Would you please prepare such a response and forward it to me by COB ~~6/24~~ 6/27

Thanks.

(until CT rtas, per Judy)
SD
6/14

June 6, 1983

Dear Mr. Rowland:

Thank you for your letter requesting clarification of our position on your legislation for reclassifying the drug methaqualone.

I appreciate your bringing your concerns to our attention. I have taken the liberty of sharing your letter with the Office of Policy Development here, and should be hearing further following the necessary review.

With best wishes,

Sincerely,

Kenneth M. Duberstein
Assistant to the President

The Honorable J. Roy Rowland
House of Representatives
Washington, D.C. 20515

KMD:CMP:dps

cc: w/copy of inc, Ed Harper --ATTN:
CARLTON TURNER-- for DRAFT response

WH RECORDS MANAGEMENT WILL RETAIN ORIGINAL
INCOMING

5
ND
J. ROY ROWLAND
8TH DISTRICT, GEORGIA

COMMITTEES:
PUBLIC WORKS AND TRANSPORTATION
VETERANS' AFFAIRS

WASHINGTON OFFICE:
513 CANNON HOUSE OFFICE BUILDING
WASHINGTON, D.C. 20515
(202) 225-6531

139381

Congress of the United States
House of Representatives
Washington, D.C. 20515

DISTRICT OFFICES:
ROOM 203, FEDERAL BUILDING
DUBLIN, GEORGIA 31021
(912) 276-0024

POST OFFICE BOX 8258
MACON, GEORGIA 31208
(912) 743-0150

ROOM 207, FEDERAL BUILDING
WAYCROSS, GEORGIA 31501
(912) 285-8420

May 19, 1983

Mr. Kenneth M. Duberstein
Assistant to the President
for Legislative Affairs
The White House
1600 Pennsylvania Avenue, N.W.
Washington, D. C. 20500

Dear Mr. Duberstein:

In light of recent conversations with Randy Davis and Doctor Carlton Turner of the White House, I find it necessary to bring to your attention the serious concerns I have regarding official White House policy on legislation I have introduced to reclassify the drug methaqualone.

Although Mr. Davis has been extremely helpful in resolving a rather confusing matter, I feel I must express my opinion that certain actions taken by Doctor Turner involving this bill appear to be somewhat contradictory in nature.

At the heart of my concern is legislation I have introduced which would move methaqualone from Schedule II to I of the Controlled Substances Act. In previous communication with Doctor Turner, I was advised that the Administration's position was that this action was administrative and under the jurisdiction of the Food and Drug Administration. However, I was further advised that there would be no efforts to actively oppose the bill.

Unfortunately, some weeks later I discovered that a national parents' organization was expressly requested by Doctor Turner to halt the release of a newsletter urging support of this legislation. Now I certainly share Doctor Turner's concern that constituents be well-informed on issues in which they contact Members of Congress; but, in my opinion Doctor Turner's action in this regard constitutes active opposition.

Therefore, I believe written clarification of the official White House position on H.R. 1097 would be in order. I am confident that this course of action will prevent any further misunderstanding of the position of the Administration.

Sincerely,


J. ROY ROWLAND

THE WHITE HOUSE

WASHINGTON

May 23, 1983

139947PD

4900

H9006-21

WE

WE

RE

Dear Mr. Stolz:

Thank you for taking a strong interest in the problem of drug abuse. The American Camping Association has a unique opportunity to reach the nation's youth.

As you know, DC Comics developed a Teen Titans drug awareness comic book, made possible by a grant from the Keebler Company. The supply of these is now depleted, however DC Comics is preparing similar packages; funded by IBM and the National Federation of Parents for Drug Free Youth for the fifth grade and the National Soft Drink Association for the sixth grade. Steve Jacobs is coordinating these books for us and should be able to provide any additional information you may need.

Although we have talked on the phone and discussed some themes you want to do, I am not familiar with the specifics of your program and therefore cannot address it. The President and the Mrs. Reagan have repeatedly stated that no distinction should be made between "hard" or "soft" drugs. The use of illegal drugs is harmful to our bodies and minds and this Administration feels strongly that there is no such thing as responsible use.

I would be glad to meet with you to discuss your finalized program in detail. However, please understand that the White House cannot endorse any group or organization. The problems caused by drug abuse are serious and the fate of an entire generation rests on the success we have in educating young people to make a choice to "stay drug free." We encourage all efforts, both public and private, to meet the goal of creating a generation free from these problems and do support any concept that will allow us to reach this goal. Please do not hesitate to contact me in the future if this office can be of any assistance. Thanks again for your efforts and concerns.

Sincerely,



Carlton E. Turner, Ph.D.
Special Assistant to the President
for Drug Abuse Policy

A

Mr. Alan J. Slotz
Legislative Chairperson
x American Camping Association
Five Lockwood Circle
Westport, CT 06880

Ann - Monday

american camping association

May 6th 1983

ALAN J. STOLZ
LEGISLATIVE CHAIRPERSON

FIVE LOCKWOOD CIRCLE
WESTPORT, CT 06880

WESTPORT, CT 203/226-4389
NEW YORK, NY 212/697-3980
W. OSSIPPEE, NH 603/539-4997

Ms. Sheryl Emerly
Office of Mrs. Nancy Reagan
213 East Wing
The White House
Washington, D. C. 20500

Dear Ms. Eberly;

Nice to chat with you yesterday, and I appreciate your interest in the drug education program being launched this month by the American Camping Association. As you know, several of us are on the same tact, and after meeting with Steve Jacobs yesterday, I know that Dr. Turner is also very supportive. Ann Wrobelleski also has my initial information, and as she introduced me to Joyce Nalepka, our mailing to children's summer camps across the country will include distribution literature from the National Federation of Parents For Drug Free Youth, and Mrs. Reagan's listing of public speakers.

As the volunteer who initiated the programs for children in summer camps, it seems to now be my chore to coordinate all parties concerned, that we may rapidly gather the materials needed for promotion and mailing, which in turn allows camp operators to take part in a drug prevention, education program this summer. Time is short! May I therefore ask for the cooperation of your office in two initial ways?

First, per our chat, I am enclosing a draft letter for Mrs. Reagan which is self-explanatory. I would like this letter as a cover message in the packet we shall send to each of the some 9,500 camp directors in the United States. I'd also like a file photo of the First Lady to reproduce with the letter, and the mailing will include the speaker's lists and the "Federations" samples of literature.

Second, I would like to have a photo-taking meeting with Mrs. Reagan, and of course we'd fly to Washington for the earliest possible convenient date. The photos and a press release would then be distributed to the media by our public affairs office and also be used in professional journals and magazines to youth leaders and camp executives. At such a meeting I'd be joined by Mr. Armand Ball Jr, our Executive Vice President and by Mr. Charles Kujawa, our National President. Perhaps Dr. Turner and Mr. Jacobs could also attend with Mrs. Nalepka, as we are using their materials in this effort.

We also have ideas to expand the use of the new comic book, and the upcoming drama-plays & scripts to the camp setting, to further enhance the educational activity, and look foward to working out that phase shortly.

May I hear from you on the above? I may best be reached at my home office in Westport, Connecticut, and with thanks in advance for your assistance, I remain,

Sincerely yours,

Alan J. Stolz, CCD, National Legislative Chairman

CC: All Parties

Bradford Woods, Martinsville, Indiana 46151 (317) 342-8456

NATIONAL STAFF

Armand B. Ball, Executive Vice President
Michael C. Kromer, Director of Business Operations
Glenn T. Job, Director of Communications
Kay Kester-Oliver, Director of Member Services



TO: Sheryl Eberly
FROM: Alan Stolz
RE: DRAFT of Letter from Mrs Reagan to the summer camp directors

May 7th 1983

Dear Camp Director;

I am truly pleased to invite you to participate in the American Camping Association's new program to provide information for your campers this summer, in an effort to prevent drug abuse among youth. It is with a deep, personal feeling that we must all join the effort to eradicate drug abuse that I send this letter to you and your colleagues in summer camps, and I consider it a privlidge to help sponsor such a national effort that will give facts and guidance to millions of boys and girls attending America's youth camps this summer.

Ten thousand of our country's childrens camps form a uniquely American educational experience, effecting more children than any other organized youth activity outside the family and school systems. You and your fellow camping professionals will directly influence eight and one-half million campers and young adult staff members in the months ahead. I urge you to use the materials provided by the American Camping Association and the National Federation of Parents For Drug Free Youth, as programs that are informative for prevention. I know that drug abuse is not a problem in the summer camp setting, but in your intimate atmosphere you can establish a close rapport and teaching relationship with youngsters not usually found in the formal classroom or home community. Youth camp leaders like yourself have a marvelous opportunity to provide facts and guidance to prevent drug abuse that will positively influence the lives of your young people in all their years ahead.

I heartily commend the American Camping Association's initiative and leadership efforts to prevent drug abuse with children, by using the summer camp setting as a course of learning and influence. I hope that you will make use of my list of speakers, and the distribution literature as sampled in this packet. Summer camps teach skills for personal growth as well as skills in sports, in waterfront and in appreciation of America's outdoor invironment. I beleive that your camp can now offer an added learning experience by helping our nation's youth lead drug free lives.

What a wonderful opportunity you have at camp to benefit all those who are in your care this summer! My very best wishes to you for a happy and healthy camp season!

Sincerely yours,

Nancy Reagan

OFFICE OF POLICY DEVELOPMENT

STAFFING MEMORANDUM

DATE: 6/1/83

ACTION/CONCURRENCE/COMMENT DUE BY: fyi

SUBJECT: Gene Rossides

Breakfast

	ACTION	FYI		ACTION	FYI
HARPER	☐	☐	DRUG POLICY	☐	☐
PORTER	☐	☐	✓ TURNER	☐	☐
BARR	☐	☐	D. LEONARD	☐	☐
BLED SOE	☐	☐	OFFICE OF POLICY INFORMATION		
BOGGS	☐	☐	HOPKINS	☐	☐
BRADLEY	☐	☐	PROPERTY REVIEW BOARD	☐	☐
CARLESON	☐	☐	OTHER		
DENEND	☐	☐		☐	☐
GALEBACH	☐	☐		☐	☐
GARFINKEL	☐	☐		☐	☐
GUNN	☐	☐		☐	☐
B. LEONARD	☐	☐		☐	☐
LI	☐	☐		☐	☐
McALLISTER	☐	☐		☐	☐
MONTOYA	☐	☐		☐	☐
ROPER	☐	☐		☐	☐
SMITH	☐	☐		☐	☐
SWEET	☐	☐		☐	☐
UHLMANN	☐	☐		☐	☐
ADMINISTRATION	☐	☐		☐	☐

REMARKS: Ed, I met with Gene (6-30-83). We discussed the range of drug abuse subjects. Gene has some good ideas. Dick will discuss one suggestion with IRS. Gene wants to do away with DEA and does not believe our efforts have been anything of substance; only media events. He admitted that the programs could work. We will continue our dialogue. See attached memo.

Please return this tracking from Gene to Casey 1-7-81

Edwin L. Harper
Assistant to the President
for Policy Development
(x6515)

7-5-83

THE WHITE HOUSE

WASHINGTON

June 1, 1983

MEMORANDUM FOR CARLTON TURNER

FROM: EDWIN L. HARPER 

SUBJECT: Gene Rossides

Carlton, would you please invite Eugene Rossides from Rogers & Wells, 1737 H Street, N.W., Washington, D.C. 20006; (phone - 331-7760) over for a lunch or breakfast. I'm sure you recall Rossides' past involvement in drug activities. I'd appreciate your getting his views and then discussing them with me when we have a chance.

WCC
6/17 10:10

January 27, 1981

TO: William J. Casey

FROM: Eugene T. Rossides *EAR*

SUBJECT: Drug Law Enforcement Opportunity for the Reagan Administration--Improve Enforcement while Reducing Budget Expenditures by \$200,000,000 annually

You asked me for a policy paper on how the Federal Government can best handle drug law enforcement based on my four years' experience as Assistant Secretary of the Treasury for Enforcement, Tariff & Trade Affairs, and Operations (1969-1973).

A Preliminary Statement and the Summary of Program and Policy Recommendations are set forth in 7 1/2 pages. It takes less than 10 minutes to read.

Preliminary Statement

The Reagan Administration has a unique opportunity to improve drug law enforcement significantly and at the same time to reduce budget expenditures in this regard by over \$200,000,000 annually. The reduction in manpower is estimated at over 3,000.

I am in general agreement with most of Keith Adkinson's Transition Report on the Drug Enforcement Administration (DEA). The DEA is generally recognized as a failure. Its basic approach--to stop drugs at the source--has not worked and cannot work. DEA's

approach has probably stimulated more production and more interest in smuggling illicit drugs into the U.S. Priorities must be reversed. Domestically DEA's incursion on state and local policy responsibility is counterproductive. DEA's anti-drug smuggling efforts have been weak and can never achieve the expertise of Customs to whom that responsibility should be returned.

The DEA is one of the prime examples of government bureaucracy gone wrong--of "unnecessary and excessive growth of government"--at great cost to the taxpayer. It is not simply a question of improving management. It should never have been created. To correct the situation and have an effective Federal drug enforcement effort requires, in my judgment, the abolition of the DEA and the transfer to other agencies of those Federal functions that should remain in existence. DEA manpower would be reduced by 3,000 out of over 4,000 with an annual budget expenditure reduction of \$150,000,000.

The Reorganization Plan of 1973 created DEA by combining the Bureau of Narcotics and Dangerous Drugs (BNDD), Customs anti-drug smuggling responsibilities, the Office of Drug Abuse Law Enforcement (ODALE), a clumsy Federal effort against street traffickers which the Federal Government had no business being involved in, and the Office of National Narcotics Intelligence (ONNI). That Plan was part of a misguided effort to put all law enforcement in the Department of Justice. It must be reversed if we are to improve our chances against the organized drug traffickers.

Reorganization Plan No. 1 of 1968, which combined Treasury's

Bureau of Narcotics and FDA's Bureau of Drug Abuse Control into the Bureau of Narcotics and Dangerous Drugs under the Department of Justice was a politically motivated public relations action designed to give the impression in early 1968 that President Johnson was doing something about drug abuse problems. It was a costly mistake for which we are still paying.

Summary of Program and Policy Recommendations

Drug trafficking involves at least three areas of law violations:

- smuggling
- substantive drug violations
- income tax evasion.

The following six-point program is proposed in order to ensure the most effective Federal enforcement effort possible against drug trafficking. These proposals while strengthening enforcement will actually reduce Federal manpower by over 3,000 and Federal expenditures by over \$200,000,000 annually. It should be implemented now as the timing is highly appropriate. It should be done on a low-key basis without fanfare or predictions.

1. Return anti-drug smuggling responsibilities to Customs

A high priority should be placed on preventing drugs from being smuggled into the United States. To accomplish this objective a necessary condition is the return to the experts in Customs of the anti-drug smuggling responsibilities now in DEA. Few, if any, additional personnel are needed by Customs. This will result in a manpower saving of several hundred positions.

The DEA anti-drug smuggling effort has been weak and can never match the expertise of Customs nor the world-wide network of contacts and cooperation with customs agencies around the world that the U.S. Customs Service has (the Customs Cooperation Council located in Brussels has 89 members).

There is no sound argument I know of not to return this responsibility to Customs as soon as possible.

2. Domestic U.S. Drug Enforcement

The major responsibility for internal U.S. drug enforcement rests with the over 500,000 state and local law enforcement officers. DEA's incursion on that responsibility has diluted it and has resulted in poorer enforcement. The Reagan Administration should stress the state and local responsibility for domestic drug enforcement and support them in their effort. State and local enforcement officials are fully capable of handling major cases as well as street-level work.

The Federal effort in the United States should concentrate on major traffickers only and should give full cooperation to state and local officials. Federal agents should respond to requests for assistance from state and local officials and not preempt major cases initiated by them. The policy should be that state and local officials are in charge and the Federal Government stands ready to assist. Federal agents should concentrate on major traffickers that state and local enforcement officials are not handling. Such an effort would not require more than a few hundred agents and support

personnel. This responsibility should be transferred from DEA to the FBI, the Bureau of Alcohol, Tobacco & Firearms, or Customs.

The ODALE street trafficker program, incorporated later into the DEA, was a serious error of policy. It was a costly public relations gimmick which was done for political purposes. The Federal Government should not get involved in middle-level and street-level substantive drug trafficking cases.

The reduction in Federal manpower by recognizing the primacy of state and local enforcement officials for domestic drug enforcement would be about 2,000.

3. Attack, through the tax laws, the profits of the illicit drug traffic.

An effective tax program, criminal and civil, aimed at carefully selected major targets can be handled with a total of 450 man years in agent and support personnel. The tax program aimed at the minor dealers through tax action can be handled basically through existing assessment and collection programs.

We proved in 1971-72 during the last two years of my four-year tenure as Assistant Secretary that this program was the most effective weapon against the drug traffickers and that it more than paid for itself in actual receipts from assessments and collections. Unfortunately, after I left Treasury, the new Commissioner of Internal Revenue scuttled the program. The tax program aimed at the illicit profits of the drug traffickers, which are taxable, is an essential element of a multi-dimensional Federal approach. Without it no overa Federal approach can succeed.

4. Border Management Agency

There have been serious and competent studies regarding border management. I concur with the recommendation to create a Border Management Agency under the Treasury Department combining Immigration's border inspection, patrol and investigative elements and Customs border operations as it would result in more effective enforcement at reduced cost. (The immigration regulatory and adjudicatory functions would remain in the Department of Justice.) A necessary condition is the return to the Customs experts of anti-drug smuggling responsibilities. I do not have estimates of the reductions in manpower and budget expenditures that would result; however, they should be substantial. A prudent businessman would have done this long ago.

5. International

a. Utilize diplomacy and the United Nations to press producing and transit countries to put their own houses in order at their own expense. Giving money and equipment to foreign governments has not worked and has probably stimulated more production around the world. Our Ambassadors in the relevant countries should have drug enforcement as a high priority item. The State Department budget for drug assistance to foreign governments is about 35 million dollars. It should be eliminated.

b. DEA has over 275 agents overseas which is about 15% of its oversized agent force. Many of these overseas agents get involved in handling cases with and without their counterparts in the host

country. We have no legal right to run cases overseas and we should not do so. That is the responsibility of the foreign country law enforcement officials which is diluted when we get involved. We must stop Americanizing world drug problems. It is not our responsibility to police the world drug traffic.

The basic function of agents overseas is and should be strictly the gathering of tactical intelligence on potential smuggling operations into the United States in cooperation with the host country officials. The number of agents needed is between 25 and 35. The reduction in manpower would be about 250.

c. CIA intelligence function

The CIA has great capability for gathering strategic drug intelligence. It was given that responsibility in about 1970. That role should continue and should be given a high priority.

6. The remaining drug regulatory functions of DEA should be returned to the Food & Drug Administration. The Department of Justice should not be in the drug regulatory business.

A program made up of these recommendations can be quickly implemented. From the time a policy decision to move ahead is made, it could be achieved within three to four months, including any required legislation.

Timing is important. I urge expeditious action on a low-key basis. DEA has an effective lobbying operation with various members

of Congress and can stimulate letters from state and local officials to whom it has given money and resources under Federal programs. However, if the Administration were to adopt these proposals I do not foresee serious opposition in the Congress.

In summary, the above program will strengthen drug law enforcement while reducing Federal manpower by over 3,000 and Federal budget expenditures by over \$200,000,000 annually.

Knowing the time constraints on the policy officials, I have tried to keep this memorandum as brief as possible. However, each of these proposals can be expanded upon at length.

DOCUMENT NO.

140352

TR

PD

HE006-01

OFFICE OF POLICY DEVELOPMENT

FG006-07

STAFFING MEMORANDUM

DATE: 6/1/83

ACTION/CONCURRENCE/COMMENT DUE BY: fyi

SUBJECT: Eugene (Gene) Rossides

from Rogers & Wells - involved in drug activities - please meet & then discuss his views with me

	ACTION	FYI		ACTION	FYI
HARPER	☐	☐	DRUG POLICY	☐	☒
PORTER	☐	☐	✓ TURNER	☐	☒
BARR	☐	☐	D. LEONARD	☐	☒
BLEDSON	☐	☐	OFFICE OF POLICY INFORMATION		
BOGGS	☐	☐	HOPKINS	☐	☐
BRADLEY	☐	☐	PROPERTY REVIEW BOARD	☐	☐
CARLESON	☐	☐	OTHER		
DENEND	☐	☐		☐	☐
GALEBACH	☐	☐		☐	☐
GARFINKEL	☐	☐		☐	☐
GUNN	☐	☐		☐	☐
B. LEONARD	☐	☐		☐	☐
LI	☐	☐		☐	☐
McALLISTER	☐	☐		☐	☐
MONTROYA	☐	☐		☐	☐
ROPER	☐	☐		☐	☐
SMITH	☐	☐		☐	☐
SWEET	☐	☐		☐	☐
UHLMANN	☐	☐		☐	☐
ADMINISTRATION	☐	☐		☐	☐

REMARKS:


Please return this tracking
sheet with your response

Edwin L. Harper
Assistant to the President
for Policy Development
(x6515)

THE WHITE HOUSE
WASHINGTON

June 1, 1983

MEMORANDUM FOR CARLTON TURNER

FROM: EDWIN L. HARPER 
SUBJECT: Gene Rossides

Carlton, would you please invite Eugene Rossides from Rogers & Wells, 1737 H Street, N.W., Washington, D.C. 20006; (phone - 331-7760) over for a lunch or breakfast. I'm sure you recall Rossides' past involvement in drug activities. I'd appreciate your getting his views and then discussing them with me when we have a chance.